London:
Britain’s healthcare regulator will examine all the information from trials of the COVID-19 vaccine created by Oxford and AstraZeneca, like which dosing regimen is greatest to use, the regulator’s chief executive stated on Wednesday.
“Our regulatory review is all encompassing We will look at all available data,” June Raine, chief executive of the Medicines and Healthcare items Regulatory Agency (MHRA), told lawmakers following a study showed the vaccine had efficacy of 62% for trial participants offered two complete doses, but 90% for a smaller sized sub-group offered a half, then a complete dose.
“Clearly, we have great interest into the possible reasons for the different doses having a different efficacy,” she stated.
“The position is we will look at every piece of evidence part of that will be to examine with great rigour, the basis for the appropriate dosage regimen,” she added.
()